Nilotinib Viatris

Nilotinib, the active ingredient in Nilotinib Viatris, is a tyrosine kinase inhibitor presented as a tablet for oral use. It selectively targets the BCR‑ABL protein and is indicated for the treatment of chronic myeloid leukemia in adult patients.\n\nGNH India supplies Nilotinib Viatris as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Nilotinib is a targeted therapy that acts on the BCR‑ABL tyrosine‑kinase pathway in chronic myeloid leukemia.\n\nChronic Myeloid Leukemia (CML): Improves hematologic, cytogenetic and molecular response rates, helping to achieve disease control in patients with Philadelphia chromosome‑positive disease.

Nilotinib may cause a range of adverse reactions that vary in frequency and severity.\n\nCommon Side Effects:\n- Nausea and vomiting\n- Diarrhea or constipation\n- Rash or pruritus\n- Headache\n- Fatigue or asthenia\n- Myalgia or arthralgia\n\nSerious or Rare Side Effects:\n- Cardiovascular events such as arterial occlusive disease\n- Pancreatitis\n- Severe hepatic injury\n- QT‑interval prolongation and arrhythmias\n- Severe infections or sepsis\n- Tumor lysis syndrome

Before initiating therapy, clinicians should assess patient‑specific risk factors and monitor relevant parameters.\n\nMonitor cardiac function: baseline ECG and periodic QT assessment\nMonitor liver enzymes: check ALT/AST before treatment and during therapy\nMonitor blood glucose: watch for hyperglycemia, especially in diabetic patients\nAvoid in patients with known prolonged QT interval or significant cardiac disease\nUse caution in hepatic or renal impairment: dose adjustment may be required\nStore at ambient temperature: keep in original container, protect from moisture and direct sunlight

Nilotinib interacts with several drug classes that can alter its plasma concentration or increase toxicity.\n\nMajor Interactions (Avoid):\n- Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin)\n- Strong CYP3A4 inducers (e.g., rifampicin, carbamazepine)\n- Acid‑reducing agents (e.g., high‑dose PPIs, H2 blockers) taken within 2 hours of nilotinib\n\nModerate Interactions (Monitor Closely):\n- Anticoagulants such as warfarin (INR monitoring)\n- Statins (especially simvastatin, lovastatin) – risk of myopathy\n- Antihypertensives (e.g., calcium channel blockers) – potential blood pressure changes\n- Oral contraceptives – reduced efficacy\n- Digoxin – increased serum levels